Brokers Offer Predictions for Kura Oncology Q2 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Leerink Partnrs issued their Q2 2025 earnings estimates for Kura Oncology in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of $0.14 for the quarter. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology's Q3 2025 earnings at ($0.08) EPS and Q4 2025 earnings at ($0.06) EPS.

KURA has been the topic of several other reports. Jefferies Financial Group decreased their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, November 21st. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. Stifel Nicolaus cut shares of Kura Oncology from a "buy" rating to a "hold" rating and decreased their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, HC Wainwright raised their price objective on Kura Oncology from $37.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $27.13.

Kura Oncology Price Performance

Shares of NASDAQ KURA traded down $0.43 during midday trading on Friday, hitting $8.36. The company had a trading volume of 792,869 shares, compared to its average volume of 1,860,166. The business has a 50-day simple moving average of $8.69 and a two-hundred day simple moving average of $14.87. Kura Oncology has a twelve month low of $6.98 and a twelve month high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $650.31 million, a price-to-earnings ratio of -3.54 and a beta of 0.78.

Insider Activity

In related news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company's stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,255 shares of company stock worth $100,739. Corporate insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Kura Oncology during the third quarter valued at $25,000. E Fund Management Co. Ltd. acquired a new position in shares of Kura Oncology in the 4th quarter valued at $90,000. Corient Private Wealth LLC bought a new stake in shares of Kura Oncology in the 4th quarter valued at $109,000. Teacher Retirement System of Texas grew its stake in Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock valued at $120,000 after acquiring an additional 2,285 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after acquiring an additional 1,750 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.